Mangoceuticals, Inc. (MGRX) Income Statement
MGRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMGRX revenue and net income
Where MGRX's revenue goes
2025Each bar shows an amount and its share of revenue. MGRX kept −4,526.9% of revenue as net income.
MGRX profit margins
MGRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −26.0% | +270.9% | — | — |
| Gross profit | −34.1% | +272.4% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MGRX quarterly EPS vs estimates
Next report: November 13, 2026.
MGRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $456,021 | $615,873 | $731,493 | $8,939 | $0 |
| Cost of revenue | $205,635 | $235,909 | $299,992 | $4,089 | — |
| Gross profit | $250,386 | $379,964 | $431,501 | $4,850 | — |
| Sales, general & admin | $16.7M | $7.9M | $5.4M | $2.0M | $70,080 |
| Total operating expenses | $19.4M | $8.4M | $9.7M | $2.0M | $17,520 |
| Operating income | −$19.2M | −$8.0M | −$9.2M | −$2.0M | −$17,520 |
| Interest expense | $103,513 | $13,700 | $0 | $6,473 | $181 |
| Income before taxes | −$20.6M | −$8.7M | −$9.2M | −$2.0M | −$17,701 |
| Income taxes | — | — | $1 | −$224,622 | −$70,080 |
| Net income | −$20.6M | −$8.7M | −$9.2M | −$2.0M | −$17,701 |
| EBITDA | −$18.8M | −$8.0M | −$8.1M | −$2.0M | −$17,520 |
| EPS (diluted) | −$2.71 | −$5.00 | −$5.77 | −$0.08 | −$0.02 |
| Gross margin | 54.9% | 61.7% | 59.0% | 54.3% | — |
| Operating margin | −4,200.5% | −1,294.4% | −1,260.3% | −22,279.7% | — |
| Net margin | −4,526.9% | −1,413.6% | −1,259.4% | −22,352.1% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68,757 | $67,864 | $94,360 | $84,246 | $168,109 | $109,306 | $105,247 | $133,368 | $163,163 | $214,095 | $244,374 | $245,160 |
| Cost of revenue | $24,542 | $38,863 | $46,885 | $33,347 | $78,161 | $47,242 | $25,144 | $50,697 | $93,371 | $66,697 | $101,791 | $100,571 |
| Gross profit | $44,215 | $29,000 | $47,475 | $50,899 | $89,948 | $62,064 | $80,103 | $82,671 | $69,792 | $147,398 | $142,583 | $144,589 |
| Research & development | — | — | — | — | — | — | $171,861 | $188,782 | $239,520 | $361,740 | — | $70,599 |
| Sales, general & admin | $569,991 | $1.1M | $412,327 | $416,293 | $5.3M | $3.5M | $1.6M | $1.6M | $2.0M | $1.6M | $1.6M | $1.7M |
| Total operating expenses | $1.1M | $3.2M | $1.6M | $7.6M | $5.4M | $4.9M | $1.8M | $1.8M | $2.2M | $2.5M | $2.8M | $1.9M |
| Operating income | −$1.0M | −$3.1M | −$1.5M | −$7.5M | −$5.3M | −$4.9M | −$1.7M | −$1.8M | −$2.2M | −$2.4M | −$2.6M | −$1.8M |
| Interest income | — | $0 | — | — | — | $13,700 | — | $0 | $0 | $0 | — | $0 |
| Interest expense | $279,891 | $276,815 | $19,663 | $75,850 | $21,700 | $13,700 | $450,598 | $241,620 | $222,678 | $6,473 | — | $0 |
| Income before taxes | −$1.3M | −$3.4M | −$2.8M | −$7.6M | −$5.4M | −$4.8M | −$1.9M | −$2.0M | −$2.4M | −$2.4M | −$2.6M | −$1.8M |
| Income taxes | — | — | — | — | — | — | $40 | — | −$345 | −$40 | — | $45,878 |
| Net income | −$1.3M | −$3.4M | −$2.8M | −$7.6M | −$5.4M | −$4.8M | −$1.9M | −$2.0M | −$2.4M | −$2.4M | −$2.6M | −$1.8M |
| EBITDA | −$767,420 | −$3.1M | −$2.3M | −$7.5M | −$4.6M | −$4.4M | −$1.7M | −$1.8M | −$2.1M | −$2.2M | — | −$1.8M |
| EPS (diluted) | −$0.09 | −$0.22 | −$0.19 | −$0.69 | −$0.54 | −$1.29 | −$1.08 | −$0.99 | −$1.37 | −$1.56 | −$1.80 | −$1.70 |
| Gross margin | 64.3% | 42.7% | 50.3% | 60.4% | 53.5% | 56.8% | 76.1% | 62.0% | 42.8% | 68.8% | 58.3% | 59.0% |
| Operating margin | −1,502.5% | −4,606.8% | −1,579.5% | −8,953.5% | −3,134.0% | −4,440.0% | −1,594.3% | −1,318.2% | −1,329.1% | −1,105.9% | −1,050.9% | −733.8% |
| Net margin | −1,909.1% | −5,014.6% | −2,935.1% | −9,042.8% | −3,221.6% | −4,427.4% | −1,850.9% | −1,498.9% | −1,465.4% | −1,105.9% | −1,050.9% | −733.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MGRX's financial statements (latest annual report filed April 1, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MGRX financial results
In fiscal year 2025 (ended December 31, 2025), Mangoceuticals reported revenue of $0.5 million, down 26.0% from the year before. It had a net loss of $20.6 million, a net profit margin of −4,526.9%. Diluted earnings per share came to −$2.71.
See the MGRX stock overview for the latest quote and news, or the MGRX chart for price history and technical indicators.
MGRX income statement FAQ
What is Mangoceuticals's annual revenue?
Mangoceuticals reported total revenue of $0.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 26.0% from $0.6 million the previous year.
Is Mangoceuticals profitable?
No. Mangoceuticals reported a net loss of $20.6 million in fiscal 2025, a net profit margin of −4,526.9%; its operating margin was −4,200.5%.
What is Mangoceuticals's gross margin?
Mangoceuticals's gross margin was 54.9% in fiscal 2025: for every $100 of revenue, Mangoceuticals kept $55 after the direct cost of its products and services.
What are Mangoceuticals's earnings per share?
Mangoceuticals earned $-2.71 per diluted share in fiscal 2025, compared with $-5.00 a year earlier.
When will Mangoceuticals report its next earnings?
Mangoceuticals is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Mangoceuticals's fiscal year end?
Mangoceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 1, 2026.